Escitalopram in Schizophrenia in OCD- Open Label Study

This study has been completed.

First Received: December 3, 2006 Last Updated: January 26, 2009 History of Changes

Sponsors and Collaborators:	BeerYaakov Mental Health Center Lundbeck Israel
Information provided by:	BeerYaakov Mental Health Center
ClinicalTrials.gov Identifier:	NCT00456937

Purpose

SSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology

Condition	Intervention	Phase
Schizophrenia	Drug: Escitalopram	Phase IV

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study

Resource links provided by NLM:

MedlinePlus related topics: Obsessive-Compulsive Disorder Schizophrenia

Drug Information available for: Benzetimide Dexetimide Citalopram hydrobromide Citalopram Escitalopram Escitalopram oxalate

U.S. FDA Resources

Further study details as provided by BeerYaakov Mental Health Center:

Estimated Enrollment:	15
Study Start Date:	July 2006
Study Completion Date:	September 2008
Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients who suffer from schizophrenia and OCD

Exclusion Criteria:

Substance abuse,
Serious medical condintions,
Being on SSRI treatment

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00456937

Locations

Israel
Beer Yaakov MHC
Beer Yaakov, Israel, 70350

Sponsors and Collaborators

BeerYaakov Mental Health Center

Lundbeck Israel

Investigators

Principal Investigator:

Rafael Octavio Stryjer, M.D.

Beer Yaakov Mental Health Center

More Information

No publications provided

Responsible Party:	Beer-Yaakov MHC ( Dr Rafael Stryjer )
Study ID Numbers:	Escitalopram-173CTIL
Study First Received:	December 3, 2006
Last Updated:	January 26, 2009
ClinicalTrials.gov Identifier:	NCT00456937 History of Changes
Health Authority:	United States: Food and Drug Administration; Israel: Israeli Health Ministry Pharmaceutical Administration

Study placed in the following topic categories:

Neurotransmitter Agents
Cholinergic Antagonists
Psychotropic Drugs
Cholinergic Agents
Serotonin Uptake Inhibitors
Citalopram
Serotonin
Schizophrenia
Muscarinic Antagonists

Anxiety Disorders
Mental Disorders
Psychotic Disorders
Peripheral Nervous System Agents
Antidepressive Agents, Second-Generation
Dexetimide
Antidepressive Agents
Obsessive-Compulsive Disorder
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Parasympatholytics
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Psychotropic Drugs
Antiparkinson Agents
Cholinergic Agents
Schizophrenia
Mental Disorders
Therapeutic Uses
Dexetimide

Antidepressive Agents, Second-Generation
Schizophrenia and Disorders with Psychotic Features
Obsessive-Compulsive Disorder
Antidepressive Agents
Citalopram
Serotonin Uptake Inhibitors
Pharmacologic Actions
Muscarinic Antagonists
Serotonin Agents
Anxiety Disorders
Autonomic Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on September 02, 2009